Clinical Benefit of Rigourous AV Delay Optimization in Patients With a Dual Chamber Pacemaker (CBRAVO)

September 12, 2015 updated by: Thijs Cools, Jessa Hospital

A Prospective, Patient Blinded, Cross-over Study of the Effect on Clinical Outcomes of AV Optimization in All Comer Ambulatory Patients With a Dual Chamber Pacemaker - The Role of Atrial Function and Interatrial Conduction Delay

Though AV optimization has become a cornerstone in optimization of patients with a cardiac resynchronization therapy (CRT) device, surprisingly the use of AV optimization in patients with a dual chamber (bicameral (BIC)) pacemaker is not fully implemented in daily clinical practice. Some patients with a BIC pacemaker have a too short AV delay (AVD), secondary to an important interatrial conduction delay (IACD), which can lead to an atrial dyssynchrony syndrome. Others have a too long AV delay, also leading to a suboptimal diastolic filling time. Some patients may not need an optimization. Our aim was to evaluate the effect of AV optimization in all comer ambulatory patients with a BIC pacemaker on clinical outcomes, with a correlation to atrial pathophysiology, since until now existing evidence only emphasizes a possible hemodynamic benefit of this non invasive intervention.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Given the high prevalence of interatrial block (WHO definition: PWD on surface ECG > 110 ms) in a general hospitalized population and especially in patient groups with tachyarrhythmias (18% and 52 % respectively), this phenomenon will be important to recognize in a BIC pacemaker patient population. Actually, the prevalence of advanced interatrial block (PWD > 120 ms with biphasic P wave morphology) is 10% in candidates for definitive pacing and 32 % in patients with a bradycardia-tachycardia syndrome. The main underlying mechanism is thought to lie in abnormalities of the Bachmann bundle resulting in partial or advanced interatrial conduction delay (IACD). A normal IACD varies between 60 and 85 ms. Two potential mechanisms are spatial dispersion of refractory periods or anisotropy resulting from scarce side-to-side electrical coupling and fibrosis disrupting the arrangement of atrial muscle fibers.

Patients with an interatrial conduction delay may have a suboptimal left atrioventricular timing due to delayed contraction of the left atrium with foreshortening of ventricular filling. This may be an issue in pacemaker patients, with our without a substrate for heart failure. Beside the loss of reduction of left atrial contraction, it might even induce neurohormonal changes due to atrial stretch and pressure thus lowering blood pressure. Coronary sinus or multisite atrial pacing, both with the aim of synchronizing right and left atrial electrical activation, have shown to (i) improve hemodynamics in patients with an important IACD, both invasively and noninvasively, and to (ii) decrease recurrences of atrial fibrillation. In patients with a conventional BIC pacemaker, prevention of left atrioventricular asynchrony can be achieved by AV optimization (lengthening of the AV delay in case of too short nominal settings) as an alternative. Though all these interventions have proven to have positive hemodynamic results until now evidence about positive effects on clinical patient outcomes are lacking.

On the other hand, some of the patients implanted with a bicameral pacemaker have a too long AV delay. As a consequence diastolic filling time is impaired. Without compromising left atrioventricular synchrony AV delay, optimal AVD (AVO) can be achieved by lengthening of the AVD with conventional methods.

In contrast to the setting of CRT, AV optimization in patients with a bicameral (BIC) pacemaker is not fully implemented in daily clinical practice. Given the proven effect on mitral inflow on echocardiography, we wanted to evaluate the effect of this non invasive intervention on patient functionality and quality of life, based on a comprehensive assessment of atrial pathophysiology.

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Limburg
      • Hasselt, Limburg, Belgium, 3500
        • Jessa Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Ambulatory all comer patient population at least 3 months after implantation of a dual chamber pacemaker
  • Programmed in a DDD(R) modus
  • Right ventricular pacing percentage of > 50%

Exclusion Criteria:

  • permanent atrial fibrillation
  • endstage chronic obstructive lung disease
  • severe psychiatric, orthopedic or neurological comorbidity
  • acute illness at the moment of inclusion
  • changes in cardiovascular medication the month before inclusion until the end of the study protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Group I
All patients were programmed in the same nominal AV delay settings (sensed AV delay 120ms, paced AV delay 150 ms) before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
Active Comparator: Group II
All patients were programmed in the same nominal AV delay settings before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in exercise capacity, expressed by oxygen uptake efficiency slope
Time Frame: baseline, 4 weeks, 8 weeks

Ergospirometry protocol:

Symptom-limited exercise testing was performed on an electronically braked cycle ergometer (eBike 1.8, GE (General Electric) Healthcare) in a non-fasting condition and under medication. All exercise tests took place at a standardized time for each patient. After 1minute (min) of rest followed by 1min of unloaded cycling, the initial load was set at 20W (Watt) for 1 min, and was increased by 10 or 20W every 2 min until exhaustion. Cycle load increments were based on previous exercise testing, aiming to yield a test duration of approximately 10min. All tests were continued to volitional fatigue and no patients were limited by angina. The recovery period lasted at least 2 minutes. A 12-lead electrocardiogram was monitored continuously (Cardiosoft 6.6); maximum heart rate was registered.

The oxygen uptake efficiency slope (OUES) was calculated using [VO2= m(log10VE)+b, where m= OUES]. VO2=oxygen consumption

baseline, 4 weeks, 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in exercise capacity, expressed by VO2max (maximal oxygen consumption)
Time Frame: baseline, 4 weeks, 8 weeks
cf. Ergospirometry protocol
baseline, 4 weeks, 8 weeks
Change in NYHA class: New York Heart Association Class
Time Frame: baseline, 4 weeks, 8 weeks
baseline, 4 weeks, 8 weeks
Change in quality of life
Time Frame: baseline, 4 weeks, 8 weeks
Quality of life, measured by a standardized Heart Qol questionnaire
baseline, 4 weeks, 8 weeks
Change in 6-Minute Walk test Distance (6MWD)
Time Frame: baseline, 4 weeks, 8 weeks
baseline, 4 weeks, 8 weeks
Change in serum brain natriuretic peptide (BNP)
Time Frame: 4 weeks, 8 weeks
4 weeks, 8 weeks
Change in left atrial function, measured by left mitral annular late diastolic peak velocity (A'm(c))
Time Frame: baseline, 4 weeks, 8 weeks
baseline, 4 weeks, 8 weeks
Change in left atrial function, measured by left atrial late diastolic peak strain (εm)
Time Frame: baseline, 4 weeks, 8 weeks
baseline, 4 weeks, 8 weeks
Change in left atrial function, measured by left atrial late diastolic peak strain rate (SRm)
Time Frame: baseline, 4 weeks, 8 weeks
baseline, 4 weeks, 8 weeks
Change in systolic pulmonary artery pressure (PAPs)
Time Frame: baseline, 4 weeks, 8 weeks
baseline, 4 weeks, 8 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of interatrial conduction delay (IACD) in the study population
Time Frame: baseline
IACD is defined as the time interval from the onset of the P wave on the ECG to the onset of A'm(c)(with A'm(c) representing the annular late diastolic peak velocities lateral mitral annular level). IACD measured this way in the study is called IACD³.
baseline
Correlation of IACD with age
Time Frame: baseline
Hypothesis: interatrial conduction time will be higher in an elderly population
baseline
Correlation of IACD with P Wave Duration (PWD)
Time Frame: baseline
All standard 12-lead ECGs were obtained using the same recorder (Schiller, CARDIOVIT AT-10 plus) set at a 50 mm/s paper speed and 2 mV (millivolt)/cm standardization. To decrease the error, we measured P-wave duration manually with calipers. The mean P-wave duration (PWD) of 3 complexes was calculated in lead II. A PWD of > 120 ms, with or without a biphid P wave morphology was considered to be pathological and used for correlation study with IACD.
baseline
Correlation of IACD with left atrial function
Time Frame: 4 weeks

Components of left atrial function, as mentioned in secondary outcomes measures, namely left mitral annular late diastolic peak velocity (A'm(c)), left atrial late diastolic peak strain (εm), left atrial late diastolic peak strain rate (SRm).

Hypothesis: the larger the IACD, the poorer the left atrial function.

4 weeks
Correlation of change in VTI(A) (velocity-time integral) after AV optimization with clinical response (measured by OUES) after AV optimization
Time Frame: baseline, 4 weeks, 8 weeks
Hypothesis: change in VTI of the A wave on mitral inflow on echocardiography is a predictor of clinical response after AV optimization.
baseline, 4 weeks, 8 weeks
Correlation of change in mitral annular late diastolic peak velocity (A'm(c)) after AV optimization with clinical response (OUES) after optimization.
Time Frame: baseline, 4 weeks, 8 weeks
Hypothesis:change in mitral annular late diastolic peak velocity (A'm(c)) after AV optimization on echocardiography is a predictor of clinical response after AV optimization.
baseline, 4 weeks, 8 weeks
Prevalence of right and left intraatrial asynchrony.
Time Frame: baseline
Intra-atrial asynchrony was defined as the differences between EMD(electromechanical delay)s'(c) and EMDt'(c) (RA asynchrony) and between EMDm'(c) and EMDs'(c) (LA asynchrony). EMDm'(c) is defined as the time interval from the onset of the P wave on the ECG to the onset of A'm(c). EMDt'(c) is defined as the time interval from the onset of the P wave on the ECG to the onset of A't(c). EMDs'(c) is defined as the time interval from the onset of the P wave on the ECG to the onset of A's(c). A't(c), A's(c) and A'm(c) are defined as the annular late diastolic peak velocities at lateral tricuspid, interatrial and lateral mitral annular level.
baseline
Role of P sense offset in IACD (interatrial conduction delay)
Time Frame: baseline
Hypothesis: the larger the IACD, the larger the P sense offset (time from P-onset to P-detection).
baseline
Change of the incidence of atrial fibrillation on a short term after rigourous AV optimization
Time Frame: baseline, 4 weeks, 8 weeks
baseline, 4 weeks, 8 weeks
Correlation between atrial pacing frequency and duration of the IACD
Time Frame: baseline
All measurements were done in sinus rhythm and during atrial pacing. IACD (and left atrial function) was also measured for each patient at an atrial pacing frequency of 75 ppm (at the time of AVD optimization).
baseline
Correlation between atrial pacing frequency and left atrial function (measured by left mitral annular late diastolic peak velocity (A'm(c)).
Time Frame: 4 weeks
All measurements were done in sinus rhythm and during atrial pacing. IACD (and left atrial function) was also measured for each patient at an atrial pacing frequency of 75 ppm (at the time of AVD optimization).
4 weeks
Correlation between IACD and pacing indication
Time Frame: baseline
Hypothesis: AV block indication might have smaller IACD compared to bradycardia tachycardia syndrome indication, since in the latter one might consider more elaborate atrial pathology.
baseline
Correlation between IACD and the length of the optimal AV delay.
Time Frame: baseline, 4 weeks
Hypothesis: the larger the IACD, the more the AV delay should be lengthened to optimize mitral inflow.
baseline, 4 weeks
Correlation between 3 distinct measurements of interatrial conduction delay (IACD)
Time Frame: baseline

IACD¹ is defined as the time interval from the onset of the P wave on the ECG to the onset of the mitral peak late (A) velocity.

IACD² is defined as the time interval from the onset of the P wave on the ECG to the onset of A'm (with A'm representing late diastolic myocardial velocity at the lateral mitral annulus level).

IACD³ is defined as the time interval from the onset of the P wave on the ECG to the onset of A'm(c)(with A'm(c) representing the annular late diastolic peak velocities lateral mitral annular level).

baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Thijs Cools, MD, Jessa hospital, Hasselt
  • Study Director: Paul Dendale, MD, PhD, Jessa hospital, Hasselt
  • Study Chair: Lieven Herbots, MD, PhD, Jessa hospital, Hasselt
  • Study Chair: Rob Geukens, MD, Jessa hospital, Hasselt
  • Study Chair: Jan Verwerft, MD, Jessa hospital, Hasselt
  • Study Chair: Tara Daerden, University Hasselt
  • Study Chair: Dominique Hansen, PhD, University Hasselt

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2013

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

June 1, 2014

Study Registration Dates

First Submitted

November 19, 2013

First Submitted That Met QC Criteria

November 23, 2013

First Posted (Estimate)

November 28, 2013

Study Record Updates

Last Update Posted (Estimate)

September 15, 2015

Last Update Submitted That Met QC Criteria

September 12, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • not yet available (Other Grant/Funding Number: Laborie)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on AV optimization

Subscribe